Back to Search
MICHAEL GREVER, M.D.
M.D.
Hematology (Internal Medicine) Physician
NPI: 1215942735IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
35.042095(OH)
Medical Oncology Physician
Internal Medicine — Medical Oncology
Code: 207RX0202X
35.042095(OH)
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
35.042095(OH)
Education
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
Class of 1971
Research & Publications (20)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
PMID 17283363·J Clin Oncol·2007
3-trial
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.
PMID 17707839·Best Pract Res Clin Haematol·2007
8-other
Pentostatin: impact on outcome in hairy cell leukemia.
PMID 16990110·Hematol Oncol Clin North Am·2006
6-review
Pentostatin in the treatment of hairy-cell leukemia.
PMID 12670468·Best Pract Res Clin Haematol·2003
4-observational
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
PMID 18854394·J Clin Endocrinol Metab·2009
3-trial
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
PMID 19604237·Br J Haematol·2009
3-trial
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
PMID 19190247·Blood·2009
7-preclinical
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
PMID 19008456·Blood·2009
3-trial
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
PMID 18981292·Blood·2009
3-trial
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
PMID 19291372·Pharm Res·2009
4-observational
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.
PMID 19261329·Leuk Res·2009
3-trial
Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.
PMID 19253275·Proteomics·2009
4-observational
Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
PMID 18635408·J Chromatogr B Analyt Technol Biomed Life Sci·2008
4-observational
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
PMID 18632723·Ann Oncol·2008
3-trial
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
PMID 18577710·Blood·2008
8-other
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
PMID 18708993·Ther Drug Monit·2008
3-trial
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
PMID 18559610·Clin Cancer Res·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 460 W 10TH AVE
COLUMBUS, OH 43210 - Phone
- (614) 293-3196
Quick Facts
- NPI
- 1215942735
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 55
- Publications
- 20
Are you this provider?
Claim Your Profile